GPB Passport icon GPB Passport icon Passport
GPB donate icon GPB donate icon Donate
Sign Up For Our Newsletter

News Articles: amyloid

This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer's-affected brain. An experimental drug modestly slowed the brain disease's progression, researchers reported Tuesday.

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

|
By:
  • Jon Hamilton
A doctor points to PET scan results that are part of Alzheimer's disease research. Much work in the field focuses a substance called beta-amyloid. A new study could test whether that's the right target.

What causes Alzheimer's? Study puts leading theory to 'ultimate test'

Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.

|
By:
  • Jon Hamilton
Dr. William Burke reviews a PET brain scan at Banner Alzheimer's Institute in Phoenix in 2018. An experimental Alzheimer's drug from Biogen and Eisai is on the verge of a Food and Drug Administration decision.

FDA Poised For Decision On Controversial Alzheimer's Drug

The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.

|
By:
  • Jon Hamilton